bionlp-st-ge-2016-spacy-parsed Home  

PMC:1064895 / 16120-16968 JSONTXT 23 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T12114 0-9 VBN denotes Increased
T12115 10-15 JJ denotes IL-17
T12116 16-26 NN denotes production
T12117 27-29 IN denotes in
T12118 30-34 NNP denotes PBMC
T12119 35-37 IN denotes of
T12120 38-46 NNS denotes patients
T12121 47-51 IN denotes with
T12122 52-54 NNP denotes RA
T12123 55-57 IN denotes by
T12124 58-66 JJ denotes anti-CD3
T12125 67-73 CC denotes and/or
T12126 74-83 JJ denotes anti-CD28
T12127 83-84 , denotes ,
T12128 85-88 CC denotes and
T12129 89-92 NNP denotes PHA
T12130 93-100 IN denotes Because
T12131 101-106 NNP denotes IL-17
T12132 107-110 VBD denotes was
T12133 111-118 RB denotes already
T12134 119-124 VBN denotes known
T12135 125-129 IN denotes from
T12136 130-137 JJR denotes earlier
T12137 138-145 NNS denotes reports
T12138 146-148 TO denotes to
T12139 149-151 VB denotes be
T12140 152-160 VBN denotes produced
T12141 161-167 RB denotes mainly
T12142 168-170 IN denotes by
T12143 171-180 VBN denotes activated
T12144 181-182 NNP denotes T
T12145 183-188 NNS denotes cells
T12146 188-189 , denotes ,
T12147 190-192 PRP denotes we
T12148 193-205 VBD denotes investigated
T12149 206-209 DT denotes the
T12150 210-216 NN denotes effect
T12151 217-219 IN denotes of
T12152 220-229 JJ denotes different
T12153 230-244 NNS denotes concentrations
T12154 245-247 IN denotes of
T12155 248-256 JJ denotes anti-CD3
T12156 257-258 -LRB- denotes (
T12157 258-259 CD denotes 1
T12158 259-260 , denotes ,
T12159 261-262 CD denotes 5
T12160 263-266 CC denotes and
T12161 267-269 CD denotes 10
T12162 270-272 NN denotes μg
T12163 272-273 NN denotes /
T12164 273-275 NN denotes ml
T12165 275-276 -RRB- denotes )
T12166 277-279 IN denotes as
T12167 280-281 DT denotes a
T12168 282-283 NNP denotes T
T12169 284-288 NN denotes cell
T12170 289-299 NN denotes activation
T12171 299-300 , denotes ,
T12172 301-306 WDT denotes which
T12173 307-313 VBD denotes showed
T12174 314-315 DT denotes a
T12175 316-330 JJ denotes dose-dependent
T12176 331-339 NN denotes increase
T12177 340-342 IN denotes in
T12178 343-348 NNP denotes IL-17
T12179 349-355 NNS denotes levels
T12180 356-357 -LRB- denotes (
T12181 357-361 NNS denotes data
T12182 362-365 RB denotes not
T12183 366-371 VBN denotes shown
T12184 371-372 -RRB- denotes )
T12185 372-373 . denotes .
T12186 374-376 IN denotes On
T12187 377-380 DT denotes the
T12188 381-386 NN denotes basis
T12189 387-389 IN denotes of
T12190 390-394 DT denotes this
T12191 394-395 , denotes ,
T12192 396-398 PRP denotes we
T12193 399-404 VBD denotes chose
T12194 405-407 CD denotes 10
T12195 408-410 NN denotes μg
T12196 410-411 NN denotes /
T12197 411-413 NN denotes ml
T12198 414-416 IN denotes as
T12199 417-418 DT denotes a
T12200 419-430 NN denotes stimulation
T12201 431-444 NN denotes concentration
T12202 445-448 IN denotes for
T12203 449-457 JJ denotes anti-CD3
T12204 457-458 . denotes .
T12205 459-461 IN denotes As
T12206 462-467 VBN denotes shown
T12207 468-470 IN denotes in
T12208 471-476 NNP denotes Table
T12209 477-478 CD denotes 1
T12210 478-479 , denotes ,
T12211 480-488 JJ denotes anti-CD3
T12212 489-502 RB denotes significantly
T12213 503-514 JJ denotes upregulated
T12214 515-520 NN denotes IL-17
T12215 521-531 NN denotes production
T12216 532-534 IN denotes up
T12217 535-537 TO denotes to
T12218 538-546 CD denotes 3.7-fold
T12219 546-547 , denotes ,
T12220 548-551 CC denotes and
T12221 552-555 DT denotes the
T12222 556-567 NN denotes combination
T12223 568-570 IN denotes of
T12224 571-580 JJ denotes anti-CD28
T12225 581-584 CC denotes and
T12226 585-593 JJ denotes anti-CD3
T12227 594-602 VBN denotes produced
T12228 603-607 RBR denotes more
T12229 608-613 JJ denotes IL-17
T12230 614-615 -LRB- denotes (
T12231 615-628 RB denotes approximately
T12232 629-634 CD denotes 1.3-1
T12233 634-636 SYM denotes .5
T12234 636-637 : denotes -
T12235 637-641 VB denotes fold
T12236 641-642 -RRB- denotes )
T12237 643-647 IN denotes than
T12238 648-656 JJ denotes anti-CD3
T12239 657-662 RB denotes alone
T12240 662-663 . denotes .
T12241 664-675 RB denotes Furthermore
T12242 675-676 , denotes ,
T12243 677-681 WRB denotes when
T12244 682-691 VBN denotes incubated
T12245 692-696 IN denotes with
T12246 697-698 NNP denotes T
T12247 699-703 NN denotes cell
T12248 704-712 NNS denotes mitogens
T12249 713-717 JJ denotes such
T12250 718-720 IN denotes as
T12251 721-724 NNP denotes PHA
T12252 724-725 , denotes ,
T12253 726-735 VBD denotes increased
T12254 736-741 NNP denotes IL-17
T12255 742-752 NN denotes production
T12256 753-756 VBD denotes was
T12257 757-761 RBR denotes more
T12258 762-772 JJ denotes pronounced
T12259 773-777 IN denotes than
T12260 778-782 IN denotes with
T12261 783-791 JJ denotes anti-CD3
T12262 792-795 CC denotes and
T12263 796-805 JJ denotes anti-CD28
T12264 806-807 -LRB- denotes (
T12265 807-810 CD denotes 588
T12266 811-812 CD denotes ±
T12267 813-815 CD denotes 85
T12268 816-822 IN denotes versus
T12269 823-826 CD denotes 211
T12270 827-828 CD denotes ±
T12271 829-830 CD denotes 1
T12272 831-836 NN denotes pg/ml
T12273 836-837 : denotes ;
T12274 838-839 NNP denotes P
T12275 840-841 NNP denotes <
T12276 842-846 CD denotes 0.05
T12277 846-847 -RRB- denotes )
T12278 847-848 . denotes .
R6542 T12114 T12116 amod Increased,production
R6543 T12115 T12116 amod IL-17,production
R6544 T12116 T12148 nsubj production,investigated
R6545 T12117 T12116 prep in,production
R6546 T12118 T12117 pobj PBMC,in
R6547 T12119 T12118 prep of,PBMC
R6548 T12120 T12119 pobj patients,of
R6549 T12121 T12120 prep with,patients
R6550 T12122 T12121 pobj RA,with
R6551 T12123 T12116 prep by,production
R6552 T12124 T12148 advcl anti-CD3,investigated
R6553 T12125 T12124 cc and/or,anti-CD3
R6554 T12126 T12124 conj anti-CD28,anti-CD3
R6555 T12127 T12126 punct ",",anti-CD28
R6556 T12128 T12124 cc and,anti-CD3
R6557 T12129 T12124 conj PHA,anti-CD3
R6558 T12130 T12134 mark Because,known
R6559 T12131 T12134 nsubjpass IL-17,known
R6560 T12132 T12134 auxpass was,known
R6561 T12133 T12134 advmod already,known
R6562 T12134 T12148 advcl known,investigated
R6563 T12135 T12134 prep from,known
R6564 T12136 T12137 amod earlier,reports
R6565 T12137 T12135 pobj reports,from
R6566 T12138 T12140 aux to,produced
R6567 T12139 T12140 auxpass be,produced
R6568 T12140 T12137 acl produced,reports
R6569 T12141 T12140 advmod mainly,produced
R6570 T12142 T12140 agent by,produced
R6571 T12143 T12145 amod activated,cells
R6572 T12144 T12145 compound T,cells
R6573 T12145 T12142 pobj cells,by
R6574 T12146 T12148 punct ",",investigated
R6575 T12147 T12148 nsubj we,investigated
R6576 T12148 T12148 ROOT investigated,investigated
R6577 T12149 T12150 det the,effect
R6578 T12150 T12148 dobj effect,investigated
R6579 T12151 T12150 prep of,effect
R6580 T12152 T12153 amod different,concentrations
R6581 T12153 T12151 pobj concentrations,of
R6582 T12154 T12153 prep of,concentrations
R6583 T12155 T12154 pobj anti-CD3,of
R6584 T12156 T12164 punct (,ml
R6585 T12157 T12162 nummod 1,μg
R6586 T12158 T12159 punct ",",5
R6587 T12159 T12157 prep 5,1
R6588 T12160 T12157 cc and,1
R6589 T12161 T12157 conj 10,1
R6590 T12162 T12164 nmod μg,ml
R6591 T12163 T12164 compound /,ml
R6592 T12164 T12155 appos ml,anti-CD3
R6593 T12165 T12164 punct ),ml
R6594 T12166 T12148 prep as,investigated
R6595 T12167 T12170 det a,activation
R6596 T12168 T12170 compound T,activation
R6597 T12169 T12170 compound cell,activation
R6598 T12170 T12166 pobj activation,as
R6599 T12171 T12170 punct ",",activation
R6600 T12172 T12173 nsubj which,showed
R6601 T12173 T12170 relcl showed,activation
R6602 T12174 T12176 det a,increase
R6603 T12175 T12176 amod dose-dependent,increase
R6604 T12176 T12173 dobj increase,showed
R6605 T12177 T12176 prep in,increase
R6606 T12178 T12179 compound IL-17,levels
R6607 T12179 T12177 pobj levels,in
R6608 T12180 T12179 punct (,levels
R6609 T12181 T12179 appos data,levels
R6610 T12182 T12183 neg not,shown
R6611 T12183 T12181 acl shown,data
R6612 T12184 T12181 punct ),data
R6613 T12185 T12148 punct .,investigated
R6614 T12186 T12193 prep On,chose
R6615 T12187 T12188 det the,basis
R6616 T12188 T12186 pobj basis,On
R6617 T12189 T12188 prep of,basis
R6618 T12190 T12189 pobj this,of
R6619 T12191 T12193 punct ",",chose
R6620 T12192 T12193 nsubj we,chose
R6621 T12193 T12193 ROOT chose,chose
R6622 T12194 T12195 nummod 10,μg
R6623 T12195 T12197 compound μg,ml
R6624 T12196 T12197 compound /,ml
R6625 T12197 T12193 dobj ml,chose
R6626 T12198 T12193 prep as,chose
R6627 T12199 T12201 det a,concentration
R6628 T12200 T12201 compound stimulation,concentration
R6629 T12201 T12198 pobj concentration,as
R6630 T12202 T12201 prep for,concentration
R6631 T12203 T12202 pobj anti-CD3,for
R6632 T12204 T12193 punct .,chose
R6633 T12205 T12206 mark As,shown
R6634 T12206 T12227 advcl shown,produced
R6635 T12207 T12206 prep in,shown
R6636 T12208 T12207 pobj Table,in
R6637 T12209 T12208 nummod 1,Table
R6638 T12210 T12227 punct ",",produced
R6639 T12211 T12215 nmod anti-CD3,production
R6640 T12212 T12213 advmod significantly,upregulated
R6641 T12213 T12215 nmod upregulated,production
R6642 T12214 T12215 compound IL-17,production
R6643 T12215 T12227 nsubj production,produced
R6644 T12216 T12215 prep up,production
R6645 T12217 T12216 prep to,up
R6646 T12218 T12217 pobj 3.7-fold,to
R6647 T12219 T12215 punct ",",production
R6648 T12220 T12215 cc and,production
R6649 T12221 T12222 det the,combination
R6650 T12222 T12215 conj combination,production
R6651 T12223 T12222 prep of,combination
R6652 T12224 T12227 amod anti-CD28,produced
R6653 T12225 T12224 cc and,anti-CD28
R6654 T12226 T12224 conj anti-CD3,anti-CD28
R6655 T12227 T12227 ROOT produced,produced
R6656 T12228 T12229 advmod more,IL-17
R6657 T12229 T12227 dobj IL-17,produced
R6658 T12230 T12235 punct (,fold
R6659 T12231 T12232 advmod approximately,1.3-1
R6660 T12232 T12235 nummod 1.3-1,fold
R6661 T12233 T12235 punct .5,fold
R6662 T12234 T12235 punct -,fold
R6663 T12235 T12229 appos fold,IL-17
R6664 T12236 T12235 punct ),fold
R6665 T12237 T12229 prep than,IL-17
R6666 T12238 T12237 pobj anti-CD3,than
R6667 T12239 T12238 advmod alone,anti-CD3
R6668 T12240 T12227 punct .,produced
R6669 T12241 T12253 advmod Furthermore,increased
R6670 T12242 T12253 punct ",",increased
R6671 T12243 T12244 advmod when,incubated
R6672 T12244 T12253 advcl incubated,increased
R6673 T12245 T12244 prep with,incubated
R6674 T12246 T12247 compound T,cell
R6675 T12247 T12248 compound cell,mitogens
R6676 T12248 T12245 pobj mitogens,with
R6677 T12249 T12250 amod such,as
R6678 T12250 T12248 prep as,mitogens
R6679 T12251 T12250 pobj PHA,as
R6680 T12252 T12253 punct ",",increased
R6681 T12253 T12255 amod increased,production
R6682 T12254 T12255 compound IL-17,production
R6683 T12255 T12256 nsubj production,was
R6684 T12256 T12256 ROOT was,was
R6685 T12257 T12258 advmod more,pronounced
R6686 T12258 T12256 acomp pronounced,was
R6687 T12259 T12258 prep than,pronounced
R6688 T12260 T12259 prep with,than
R6689 T12261 T12260 pobj anti-CD3,with
R6690 T12262 T12261 cc and,anti-CD3
R6691 T12263 T12261 conj anti-CD28,anti-CD3
R6692 T12264 T12263 punct (,anti-CD28
R6693 T12265 T12266 nummod 588,±
R6694 T12266 T12263 appos ±,anti-CD28
R6695 T12267 T12266 nummod 85,±
R6696 T12268 T12267 prep versus,85
R6697 T12269 T12272 nummod 211,pg/ml
R6698 T12270 T12272 nmod ±,pg/ml
R6699 T12271 T12272 nummod 1,pg/ml
R6700 T12272 T12268 pobj pg/ml,versus
R6701 T12273 T12276 punct ;,0.05
R6702 T12274 T12275 compound P,<
R6703 T12275 T12276 compound <,0.05
R6704 T12276 T12256 npadvmod 0.05,was
R6705 T12277 T12276 punct ),0.05
R6706 T12278 T12256 punct .,was